APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo

Stewart Sale, Isabel L. Fong, Carla de Giovanni, Lorena Landuzzi, Karen Brown, William P. Steward, Andreas J. Gescher

Research output: Contribution to journalArticle

Abstract

ApcMin mice are widely used for mechanism and efficacy studies associated with the development of chemopreventive agents. APC10.1 cells have been derived from ApcMin mouse adenomas and retain the heterozygous Apc genotype. We tested the hypothesis that this cell type may provide an in vitro model to predict chemopreventive activity of agents in the ApcMin mouse in vivo. The growth inhibitory properties of 14 putative colorectal cancer chemopreventive agents, tricin, apigenin, 3′,4′,5′,5,7-pentamethoxyflavone, resveratrol, curcumin, 3,4-methylenedioxy-3′,4′,5′-trimethoxychalcone (DMU135), 3,4,5,4′-tetramethoxystilbene (DMU212), celecoxib, aspirin, piroxicam, all-trans-retinoic acid, difluoromethylornithine (DFMO), quercetin and cyanidin-3-glucoside, were studied in this cell line, and the IC50 values were calculated. The IC50 values were plotted against previously published data of reduction of adenoma numbers caused by these agents in ApcMin mice. The correlation co-efficient was 0.678 (p <0.01), suggesting that there was a tentative correlation between the ability to inhibit the growth of APC10.1 cells and the ability to delay adenoma development in vivo. If this relationship is supported by using further agents, APC10.1 cells may serve in the future as an initial screen to prioritise compounds for assessing chemopreventive efficacy in ApcMin mice in vivo. Such a screen could reduce the number of animals required to find active agents, help reduce costs and increase throughput.

Original languageEnglish
Pages (from-to)2731-2735
Number of pages5
JournalEuropean Journal of Cancer
Volume45
Issue number16
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Adenoma
Celecoxib
Inhibitory Concentration 50
Eflornithine
Apigenin
Piroxicam
Curcumin
Growth
Tretinoin
Aspirin
Colorectal Neoplasms
Genotype
Costs and Cost Analysis
Cell Line
In Vitro Techniques
resveratrol
tricin
5,7,3',4',5'-pentamethoxyflavone
metochalcone
isoquercitrin

Keywords

  • APC10.1
  • Apc mouse
  • Chemoprevention

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. / Sale, Stewart; Fong, Isabel L.; de Giovanni, Carla; Landuzzi, Lorena; Brown, Karen; Steward, William P.; Gescher, Andreas J.

In: European Journal of Cancer, Vol. 45, No. 16, 11.2009, p. 2731-2735.

Research output: Contribution to journalArticle

Sale, Stewart ; Fong, Isabel L. ; de Giovanni, Carla ; Landuzzi, Lorena ; Brown, Karen ; Steward, William P. ; Gescher, Andreas J. / APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo. In: European Journal of Cancer. 2009 ; Vol. 45, No. 16. pp. 2731-2735.
@article{16843c968f4e4430a8f01ebd567cb093,
title = "APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo",
abstract = "ApcMin mice are widely used for mechanism and efficacy studies associated with the development of chemopreventive agents. APC10.1 cells have been derived from ApcMin mouse adenomas and retain the heterozygous Apc genotype. We tested the hypothesis that this cell type may provide an in vitro model to predict chemopreventive activity of agents in the ApcMin mouse in vivo. The growth inhibitory properties of 14 putative colorectal cancer chemopreventive agents, tricin, apigenin, 3′,4′,5′,5,7-pentamethoxyflavone, resveratrol, curcumin, 3,4-methylenedioxy-3′,4′,5′-trimethoxychalcone (DMU135), 3,4,5,4′-tetramethoxystilbene (DMU212), celecoxib, aspirin, piroxicam, all-trans-retinoic acid, difluoromethylornithine (DFMO), quercetin and cyanidin-3-glucoside, were studied in this cell line, and the IC50 values were calculated. The IC50 values were plotted against previously published data of reduction of adenoma numbers caused by these agents in ApcMin mice. The correlation co-efficient was 0.678 (p <0.01), suggesting that there was a tentative correlation between the ability to inhibit the growth of APC10.1 cells and the ability to delay adenoma development in vivo. If this relationship is supported by using further agents, APC10.1 cells may serve in the future as an initial screen to prioritise compounds for assessing chemopreventive efficacy in ApcMin mice in vivo. Such a screen could reduce the number of animals required to find active agents, help reduce costs and increase throughput.",
keywords = "APC10.1, Apc mouse, Chemoprevention",
author = "Stewart Sale and Fong, {Isabel L.} and {de Giovanni}, Carla and Lorena Landuzzi and Karen Brown and Steward, {William P.} and Gescher, {Andreas J.}",
year = "2009",
month = "11",
doi = "10.1016/j.ejca.2009.07.004",
language = "English",
volume = "45",
pages = "2731--2735",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "16",

}

TY - JOUR

T1 - APC10.1 cells as a model for assessing the efficacy of potential chemopreventive agents in the ApcMin mouse model in vivo

AU - Sale, Stewart

AU - Fong, Isabel L.

AU - de Giovanni, Carla

AU - Landuzzi, Lorena

AU - Brown, Karen

AU - Steward, William P.

AU - Gescher, Andreas J.

PY - 2009/11

Y1 - 2009/11

N2 - ApcMin mice are widely used for mechanism and efficacy studies associated with the development of chemopreventive agents. APC10.1 cells have been derived from ApcMin mouse adenomas and retain the heterozygous Apc genotype. We tested the hypothesis that this cell type may provide an in vitro model to predict chemopreventive activity of agents in the ApcMin mouse in vivo. The growth inhibitory properties of 14 putative colorectal cancer chemopreventive agents, tricin, apigenin, 3′,4′,5′,5,7-pentamethoxyflavone, resveratrol, curcumin, 3,4-methylenedioxy-3′,4′,5′-trimethoxychalcone (DMU135), 3,4,5,4′-tetramethoxystilbene (DMU212), celecoxib, aspirin, piroxicam, all-trans-retinoic acid, difluoromethylornithine (DFMO), quercetin and cyanidin-3-glucoside, were studied in this cell line, and the IC50 values were calculated. The IC50 values were plotted against previously published data of reduction of adenoma numbers caused by these agents in ApcMin mice. The correlation co-efficient was 0.678 (p <0.01), suggesting that there was a tentative correlation between the ability to inhibit the growth of APC10.1 cells and the ability to delay adenoma development in vivo. If this relationship is supported by using further agents, APC10.1 cells may serve in the future as an initial screen to prioritise compounds for assessing chemopreventive efficacy in ApcMin mice in vivo. Such a screen could reduce the number of animals required to find active agents, help reduce costs and increase throughput.

AB - ApcMin mice are widely used for mechanism and efficacy studies associated with the development of chemopreventive agents. APC10.1 cells have been derived from ApcMin mouse adenomas and retain the heterozygous Apc genotype. We tested the hypothesis that this cell type may provide an in vitro model to predict chemopreventive activity of agents in the ApcMin mouse in vivo. The growth inhibitory properties of 14 putative colorectal cancer chemopreventive agents, tricin, apigenin, 3′,4′,5′,5,7-pentamethoxyflavone, resveratrol, curcumin, 3,4-methylenedioxy-3′,4′,5′-trimethoxychalcone (DMU135), 3,4,5,4′-tetramethoxystilbene (DMU212), celecoxib, aspirin, piroxicam, all-trans-retinoic acid, difluoromethylornithine (DFMO), quercetin and cyanidin-3-glucoside, were studied in this cell line, and the IC50 values were calculated. The IC50 values were plotted against previously published data of reduction of adenoma numbers caused by these agents in ApcMin mice. The correlation co-efficient was 0.678 (p <0.01), suggesting that there was a tentative correlation between the ability to inhibit the growth of APC10.1 cells and the ability to delay adenoma development in vivo. If this relationship is supported by using further agents, APC10.1 cells may serve in the future as an initial screen to prioritise compounds for assessing chemopreventive efficacy in ApcMin mice in vivo. Such a screen could reduce the number of animals required to find active agents, help reduce costs and increase throughput.

KW - APC10.1

KW - Apc mouse

KW - Chemoprevention

UR - http://www.scopus.com/inward/record.url?scp=70350026889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350026889&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2009.07.004

DO - 10.1016/j.ejca.2009.07.004

M3 - Article

C2 - 19695862

AN - SCOPUS:70350026889

VL - 45

SP - 2731

EP - 2735

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 16

ER -